Oncology has always been a key area of focus for us. As the demand for our oncology expertise continues to surge, we are thrilled to announce the expansion of our devoted team.
Within the fabric of our expanding team, a key objective is to establish a dedicated group specialising in haemato-oncology. While haem-oncology has always been an integral part of what we do, we acknowledge that haematological malignancies demand a distinctive perspective. Now, more than ever, navigating the intricacies of technical advancements alongside an acute understanding of logistical limitations is essential in selecting the right teams to support. Hence, we are excited to introduce our very own ‘Haem-Team,’ (Tessa Rothwell, Margarida Duarte, Ryan Bishop and Paula Coyle) ensuring immediate access to the expertise required for these unique challenges.
To illustrate the dynamic pace of the market, Tessa Rothwell shares the topics currently capturing her attention.
- The evolving (and expanding) role of MRD – while applications are still being tested, the potential for MRD in surveillance (reducing exposure to radiological agents), guiding/tailoring treatment approaches and aiding early cancer detection remains one to watch.
- Advances in frontline DLBCL – after decades waiting, a potential new SoC emerged last year (i.e. POL-R-CHP), but temperament seems mixed; is this just the best for now vs. a gamechanger?
- Movement in multiple myeloma – it’s an exciting time for the field of multiple myeloma with new therapeutics (i.e. bispecific antibodies), CAR-T striving for incorporation into earlier lines, the search for new risk segmentation models to predict which patients need earlier CAR-T, and the evolving role and opinion on use of ASCT.
We welcome all our new members and look forward to evolving and supporting further in the dynamic world of oncology!
Contact the team at oncology@beyondblueinsight.com